| Outcome Measures: |
Primary: Number of Treatment Emergent Serious Adverse Events (TE-SAEs), TE-SAEs as evaluated by the investigator which may include but not limited to: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities., Up to one month (post infusion) | Secondary: EPC-CFU Levels, Endothelial Progenitor Cell Colony Forming Units (EPC-CFU) will be assessed from blood samples, At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365|CRP Marker Levels, C-Reactive Protein (CRP) levels will be assessed from blood samples and reported in mg/L, At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365|Circulating Angiogenic Factor Levels, Circulating Angiogenic Factor levels including Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF) and Stromal Cell-Derived Factor 1 (SDF-1) will be assessed from blood samples and reported in ng/mL, At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365|Flow Mediated Diameter Percentage (FMD%), FMD will be assessed using brachial artery ultrasound, At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365|Circulating Inflammatory Marker Levels, Circulating inflammatory marker levels including Interleukin (IL) -1 and IL-6 will be assessed from blood samples and reported in pg/mL, At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365|Tumor Necrosis Factor (TNF) Alpha Levels, Measured from blood samples (pg/mL), At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365
|
